Skip to main content

Can Rapamycin or Metformin Slow Human Ageing?




Could medicines originally developed to treat disease also help people remain healthy for longer? Scientists are investigating this possibility through research into rapamycin and metformin, two drugs that influence biological processes associated with ageing.

Both medicines have attracted attention because experiments suggest they may affect several processes involved in age-related decline. However, promising laboratory results do not establish that a drug can extend human life or prevent the conditions associated with ageing. As of 2026, neither rapamycin nor metformin has been proven to slow human ageing or extend lifespan in otherwise healthy people.

Why Are Scientists Studying Drugs That Target Ageing?

Ageing increases the risk of several chronic conditions, including cardiovascular disease, type 2 diabetes and some cancers. Researchers in geroscience investigate whether changing biological processes associated with ageing could delay several age-related diseases rather than treating each condition separately.

This approach differs from developing a medicine for one specific illness. Researchers want to know whether an intervention can extend healthspan, the period of life spent in relatively good health, as well as potentially influence lifespan.

Rapamycin and metformin are candidates because scientists already understand some of their biological effects and have substantial experience using them in clinical medicine. Researchers are now asking whether those effects could provide additional benefits in older adults without exposing healthy people to unacceptable risks.

How Does Rapamycin Affect Ageing?

Rapamycin, also known as sirolimus, was originally developed as an immunosuppressive medicine and is used in settings such as organ transplantation. Scientists became interested in its potential effects on ageing after discovering that it inhibits a cellular signalling pathway called mechanistic target of rapamycin, or mTOR.

The mTOR pathway helps regulate cell growth, nutrient use and protein production. In laboratory organisms, reducing certain mTOR signals can influence stress responses and cellular maintenance. Studies have repeatedly found that rapamycin can extend lifespan in mice, making it one of the most closely studied drug candidates in longevity research.

However, results in animals do not guarantee similar outcomes in people. Researchers still need to determine whether rapamycin can produce meaningful, lasting health benefits in healthy adults and identify which doses, if any, offer an acceptable balance between benefits and risks.

What Have Human Studies Found?

Human research has produced some encouraging but limited findings. A 2025 report from the PEARL trial examined intermittent, low-dose rapamycin in healthy adults over 48 weeks. The researchers found no significant overall change in visceral fat, although some improvements in selected measures appeared in particular treatment groups, including certain outcomes among women.

These findings do not demonstrate that participants aged more slowly or would live longer. The trial was relatively short for evaluating longevity, and its results cannot establish whether any changes translate into fewer diseases, longer lives or sustained improvements in health.

A broader review published in 2025 also concluded that available human evidence does not establish rapamycin as a proven treatment for delaying ageing in healthy adults. Larger and longer studies remain necessary.

Can Metformin Slow Ageing?

Metformin is widely prescribed to manage type 2 diabetes. It helps lower blood glucose, mainly by reducing glucose production in the liver and improving aspects of the body's response to insulin.

Scientists are investigating whether metformin might influence ageing beyond its established role in blood sugar control. Researchers have studied its effects on cellular energy regulation, metabolic signalling and other processes that may influence age-related disease.

Some observational studies have linked metformin use in people with diabetes to favourable health outcomes. However, these findings cannot establish that the drug itself causes longer life. Differences in health, medical care and other factors can influence comparisons between people who take metformin and those who do not.

Animal studies have also produced mixed results. Metformin has extended lifespan in some experimental settings, but the effect depends on factors such as the species, dose and experimental conditions. A 2025 review highlighted significant uncertainty about its anti-ageing potential, noting that follow-up research has not consistently confirmed earlier expectations.

Has Metformin Been Proven to Extend Human Lifespan?

No. Metformin has established medical uses, but scientists have not demonstrated that prescribing it to otherwise healthy people extends lifespan.

Researchers need clinical trials that measure meaningful outcomes, such as the development of age-related diseases, physical function and long-term health. Changes in blood markers alone cannot prove that a person will remain healthy for longer.

Scientists must also determine whether metformin benefits people who do not have diabetes. A drug that improves outcomes in a particular patient group may not provide the same benefit to healthy people with normal glucose regulation.

Rapamycin vs Metformin: What Is the Difference?

Although both drugs interest longevity researchers, they work differently and have different established medical uses.

Feature

Rapamycin

Metformin

Established medical use

Immunosuppression in specific clinical settings

Management of type 2 diabetes

Main biological target

mTOR signalling

Glucose regulation and metabolic pathways

Animal longevity evidence

Strong lifespan-extension evidence in mice

Mixed results across experimental models

Evidence for slowing human ageing

Not established

Not established

Important safety concerns

Infections, mouth ulcers, altered blood lipids and impaired wound healing

Gastrointestinal effects, vitamin B12 deficiency and rare lactic acidosis


Neither medicine has been approved specifically to slow ageing. Their established medical uses should not be confused with experimental attempts to extend healthspan.

What Are the Risks of Taking These Drugs for Longevity?

A medicine can affect several biological systems at once. This creates a challenge when researchers consider giving it to healthy people who may not have a condition that requires treatment.

Rapamycin can suppress immune activity and cause adverse effects involving blood lipids, blood glucose, wound healing and other functions. The risks depend on the dose, treatment schedule and individual circumstances. Lower or intermittent doses may have different effects from those used in established medical treatment, but researchers have not yet fully established their long-term safety for general longevity use.

Metformin commonly causes gastrointestinal symptoms and can contribute to vitamin B12 deficiency during prolonged use. A rare but serious complication, lactic acidosis, is more concerning in certain medical circumstances, including significant kidney impairment.

Neither drug should be started solely for anti-ageing purposes without appropriate medical assessment. Researchers have also not established that taking rapamycin and metformin together provides additional longevity benefits in humans.

What Research Needs to Happen Next?

Scientists need larger, carefully controlled clinical trials that follow participants long enough to detect meaningful differences in health. They must compare each drug with a suitable control group, monitor adverse effects and assess outcomes that matter to patients.

Researchers also need to identify which people might benefit, if any, and whether a drug's effects vary with age, existing medical conditions or treatment duration. Improvements in laboratory measurements may help guide research, but they cannot replace evidence of better health or longer survival.

The central challenge is to establish whether these medicines improve human healthspan enough to justify their risks. Until trials answer that question, both drugs remain candidates for longevity research rather than proven anti-ageing therapies.

Conclusion

Rapamycin and metformin offer scientists two different ways to investigate whether medicines can influence the biology of ageing. Rapamycin has produced notable lifespan-extension results in mice, while metformin has attracted interest because of its effects on glucose regulation and other metabolic processes.

However, neither drug has been proven to slow human ageing or extend lifespan in healthy people. The next step is rigorous clinical research that demonstrates lasting benefits, identifies risks and shows whether either medicine can help people live healthier lives for longer.



This educational content was carefully researched and prepared by the editorial team at Labari Web Education to support students, researchers, educators, and lifelong learners. Our goal is to provide practical, accurate, and easy, to, understand resources for JAMB, POSTUTME, WAEC, WAEC/GCE, NECO, undergraduate studies, postgraduate research, thesis and dissertation writing, academic success, scholarships, and career development. While every effort is made to ensure accuracy, readers are encouraged to verify official information where applicable.

Keep learning with Labari Web Education by exploring more expert guides, study materials, research tips, academic resources, and educational updates designed to help you succeed at every stage of your learning journey.

Comments